231 related articles for article (PubMed ID: 32857909)
1. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
2. Determination of the proliferative fractions in differentiating hematopoietic cell lineages of normal bone marrow.
Nies KPH; Kraaijvanger R; Lindelauf KHK; Drent RJMR; Rutten RMJ; Ramaekers FCS; Leers MPG
Cytometry A; 2018 Nov; 93(11):1097-1105. PubMed ID: 30176186
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
Li Y; Beck RC; Moore EM
Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
[TBL] [Abstract][Full Text] [Related]
6. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract][Full Text] [Related]
7. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
8. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
9. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
Rajab A; Porwit A
Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
[TBL] [Abstract][Full Text] [Related]
10. Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.
Shameli A; Dharmani-Khan P; Auer I; Shabani-Rad MT
Leuk Res; 2023 Nov; 134():107401. PubMed ID: 37774446
[TBL] [Abstract][Full Text] [Related]
11. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
12. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.
Roupie AL; de Boysson H; Thietart S; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Decaux O; d'Aveni M; Rossignol J; Galland J; Solary E; Willems L; Schleinitz N; Ades L; Dellal A; Samson M; Aouba A; Fenaux P; Fain O; Mekinian A;
Autoimmun Rev; 2020 Feb; 19(2):102446. PubMed ID: 31838164
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
14. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
15. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Xie W; Chen Z; Wang SA; Hu S; Li S; Miranda RN; Medeiros LJ; Tang G
Leuk Lymphoma; 2019 Dec; 60(12):2993-3001. PubMed ID: 31017498
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic/myeloproliferative neoplasm: a histopathological review].
Kayano H
Rinsho Ketsueki; 2018; 59(10):2084-2088. PubMed ID: 30305512
[TBL] [Abstract][Full Text] [Related]
17. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.
Mangaonkar AA; Swoboda DM; Coltro G; Lasho TL; Novotny PJ; Pophali P; Carr RM; Binder M; Finke CM; Gangat N; Al-Kali A; Begna KH; Reichard KK; Ketterling RP; Al Ali NH; Vafaii P; Zhang L; Padron E; Talati C; Patnaik MM
Leukemia; 2020 Feb; 34(2):656-661. PubMed ID: 31511613
[No Abstract] [Full Text] [Related]
19. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Ragon BK; Savona MR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
[TBL] [Abstract][Full Text] [Related]
20. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
